PURPOSE: PANVAC is a recombinant poxviral vaccine that contains transgenes for MUC-1, CEA, and 3 T-cell costimulatory molecules. This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer patients. EXPERIMENTAL DESIGN: Twenty-six patients were enrolled and given monthly vaccinations. Clinical and immune outcomes were evaluated. RESULTS: These patients were heavily pretreated, with 21 of 26 patients having 3 or more prior chemotherapy regimens. Side effects were largely limited to mild injection-site reactions. For the 12 breast cancer patients enrolled, median time to progression was 2.5 months (1-37+) and median overall survival was 13.7 months. Four patients had stable disease. One patient had a complete response by RECIST and remained on study for 37 months or more, with a significant drop in serum interleukin (IL)-6 and IL-8 by day 71. Another patient with metastatic disease confined to the mediastinum had a 17% reduction in mediastinal mass and was on study for 10 months. Patients with stable or responding disease had fewer prior therapies and lower tumor marker levels than patients with no evidence of response. For the ovarian cancer patients (n = 14), the median time to progression was 2 months (1-6) and median overall survival was 15.0 months. Updated data are presented here for one patient treated with this vaccine in a previous trial, with a time to progression of 38 months. CONCLUSIONS: Some patients who had limited tumor burden with minimal prior chemotherapy seemed to benefit from the vaccine. Further studies to confirm these results are warranted.
PURPOSE: PANVAC is a recombinant poxviral vaccine that contains transgenes for MUC-1, CEA, and 3 T-cell costimulatory molecules. This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancerpatients. EXPERIMENTAL DESIGN: Twenty-six patients were enrolled and given monthly vaccinations. Clinical and immune outcomes were evaluated. RESULTS: These patients were heavily pretreated, with 21 of 26 patients having 3 or more prior chemotherapy regimens. Side effects were largely limited to mild injection-site reactions. For the 12 breast cancerpatients enrolled, median time to progression was 2.5 months (1-37+) and median overall survival was 13.7 months. Four patients had stable disease. One patient had a complete response by RECIST and remained on study for 37 months or more, with a significant drop in serum interleukin (IL)-6 and IL-8 by day 71. Another patient with metastatic disease confined to the mediastinum had a 17% reduction in mediastinal mass and was on study for 10 months. Patients with stable or responding disease had fewer prior therapies and lower tumor marker levels than patients with no evidence of response. For the ovarian cancerpatients (n = 14), the median time to progression was 2 months (1-6) and median overall survival was 15.0 months. Updated data are presented here for one patient treated with this vaccine in a previous trial, with a time to progression of 38 months. CONCLUSIONS: Some patients who had limited tumor burden with minimal prior chemotherapy seemed to benefit from the vaccine. Further studies to confirm these results are warranted.
Authors: M von Mehren; P Arlen; J Gulley; A Rogatko; H S Cooper; N J Meropol; R K Alpaugh; M Davey; S McLaughlin; M T Beard; K Y Tsang; J Schlom; L M Weiner Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: P Arlen; K Y Tsang; J L Marshall; A Chen; S M Steinberg; D Poole; P H Hand; J Schlom; J M Hamilton Journal: Cancer Immunol Immunother Date: 2000-12 Impact factor: 6.968
Authors: James L Gulley; Philip M Arlen; Kwong-Yok Tsang; Junko Yokokawa; Claudia Palena; Diane J Poole; Cinzia Remondo; Vittore Cereda; Jacquin L Jones; Mary P Pazdur; Jack P Higgins; James W Hodge; Seth M Steinberg; Herbert Kotz; William L Dahut; Jeffrey Schlom Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Howard L Kaufman; Wei Wang; Judith Manola; Robert S DiPaola; Yoo-Joung Ko; Christopher Sweeney; Theresa L Whiteside; Jeffrey Schlom; George Wilding; Louis M Weiner Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au Journal: Breast Care (Basel) Date: 2018-01-31 Impact factor: 2.860
Authors: Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel Journal: Curr Treat Options Oncol Date: 2015-01
Authors: Michael A Morse; Donna Niedzwiecki; John L Marshall; Christopher Garrett; David Z Chang; Mebea Aklilu; Todd S Crocenzi; David J Cole; Sophie Dessureault; Amy C Hobeika; Takuya Osada; Mark Onaitis; Bryan M Clary; David Hsu; Gayathri R Devi; Anuradha Bulusu; Robert P Annechiarico; Vijaya Chadaram; Timothy M Clay; H Kim Lyerly Journal: Ann Surg Date: 2013-12 Impact factor: 12.969
Authors: Margaret E Gatti-Mays; Julius Strauss; Jeffrey Schlom; James L Gulley; Renee N Donahue; Claudia Palena; Jaydira Del Rivero; Jason M Redman; Ravi A Madan; Jennifer L Marté; Lisa M Cordes; Elizabeth Lamping; Alanvin Orpia; Andrea Burmeister; Eva Wagner; Cesar Pico Navarro; Christopher R Heery Journal: Clin Cancer Res Date: 2019-05-20 Impact factor: 12.531
Authors: Marijo Bilusic; Christopher R Heery; Philip M Arlen; Myrna Rauckhorst; David Apelian; Kwong Y Tsang; Jo A Tucker; Caroline Jochems; Jeffrey Schlom; James L Gulley; Ravi A Madan Journal: Cancer Immunol Immunother Date: 2013-12-07 Impact factor: 6.968
Authors: Christopher R Heery; Claudia Palena; Sheri McMahon; Renee N Donahue; Lauren M Lepone; Italia Grenga; Ulrike Dirmeier; Lisa Cordes; Jenn Marté; William Dahut; Harpreet Singh; Ravi A Madan; Romaine I Fernando; Duane H Hamilton; Jeffrey Schlom; James L Gulley Journal: Clin Cancer Res Date: 2017-08-30 Impact factor: 12.531